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have a bleeding tendency related to the changes in the hemostat-
ic system that occur as a consequence of the disease. However, it
has now been well established that patients with cirrhosis are at
risk for both bleeding and thrombotic complications. These
thrombotic complications include portal vein thrombosis, deep
vein thrombosis and pulmonary embolism, and coronary or cere-
brovascular infarctions. Antithrombotic drugs to prevent or treat
thrombotic complications in patients with cirrhosis have been
used only minimally in the past due to the perceived bleeding
risk. As the thrombotic complications and the necessity of anti-
thrombotic treatment in these patients are increasingly recog-
nized, the use of antithrombotic drugs in this population is
likely increasing. Moreover, given the rising incidence of fatty
liver disease and generally longer survival times of patients with
chronic liver diseases, it would be reasonable to presume that
some of these thrombotic complications may be increasing in
incidence over time. In this review, we will outline the indica-
tions for antithrombotic treatment in patients with cirrhosis. Fur-
thermore, we will discuss the available antithrombotic drugs and
indicate possible applications, advantages, and caveats. Since for
many of these drugs very little experience in patients with cirrho-
sis exists, these data are essential in the design of future clinical
and laboratory studies on mechanisms, efﬁcacy, and safety of the
various antithrombotic strategies in these patients.
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Cirrhosis is frequently associated with complex changes in the
hemostatic system. These changes include thrombocytopenia
and platelet function defects, decreased levels of pro- and antico-
agulant proteins, and alterations in the ﬁbrinolytic system. The
net result of these changes has long been thought to be a bleeding
tendency. Indeed, routine diagnostic tests of hemostasis, such as
the platelet count, and coagulation tests, such as the prothrombin
time (PT) and activated partial thromboplastin time (aPTT), indi-
cate a hypocoagulable state. Clinical experience in patients with
liver disease combined with sophisticated laboratory studies of
hemostasis has led to the conclusion that despite the major
changes in the hemostatic system associated with cirrhosis, the
net result is a system that remains in balance due to a commen-
surate decline in pro- and antihemostatic pathways. This ‘rebal-
anced’ hemostatic system in patients with cirrhosis, however,
appears much more fragile compared to the hemostatic balance
of healthy individuals (Fig. 1). This precarious hemostatic balance
explains why patients with cirrhosis may experience bleeding
complications as well as thrombotic episodes [1,2].
Until recent years, the common belief was that patients with
cirrhosis were protected against thrombotic disease as they were
‘auto-anticoagulated’ as suggested by prolonged routine tests of
hemostasis. Consequently, antithrombotic therapy to prevent or
treat thrombotic disease was used minimally. Limited use of anti-
thrombotic drugs is also explained by the perceived bleeding risk.
Nowadays, there is increasing recognition of various thrombotic
complications that may occur in patients with chronic liver dis-
eases [3–5]. With increasing rates of fatty liver disease and gen-
erally longer survival times in patients with chronic liver
diseases, it would be reasonable to presume that some of these
complications may be increasing in incidence over time. Preven-
tion or treatment of these complications is complex due to many
issues including dosing, monitoring, and safety of the available
antithrombotic agents. In this review, we will discuss the throm-
botic complications that may occur in patients with cirrhosis.
Subsequently, we will discuss advantages and disadvantages of
currently available antithrombotic drugs that potentially could
be used to treat thrombotic complications of patients with liver
disease. We would like to stress that there are no established
guidelines for treatment or prevention of thrombotic disease in13 vol. 59 j 358–366
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Fig. 1. The hemostatic balance in patients with liver disease as compared to
that of healthy individuals. This cartoon depicts the stable hemostatic balance in
healthy individuals and shows that although the hemostatic system in patients
with liver disease is (re)balanced, the balance is fragile and may easily tip to
either a hypo or hypercoagulable status.
JOURNAL OF HEPATOLOGYpatients with liver disease. In addition, there is limited clinical
data to support or refute the use of available antithrombotic
drugs for the different potential indications. We aim at giving
an overview of pros and cons of the available drugs with the
aim to provide a rationale for future studies on safety and efﬁcacy
of potential antithrombotic strategies for the different indica-
tions. In our discussion of the possible antithrombotic drugs,
we have limited ourselves to antithrombotic drugs that are rec-
ommended for venous and arterial events in the general popula-
tion in the most current guidelines, and only discuss drugs that
are generally available for clinical use.Thrombotic diseases in patients with cirrhosis
Portal vein thrombosis
A common complication of cirrhosis is development of portal vein
thrombosis (PVT), which is associated with clinical deterioration
[6]. Furthermore, PVT complicates liver transplant surgery, and
may adversely affect outcome after liver transplantation [7].
Although there are no established guidelines for treatment of
PVT in a patient with cirrhosis, anticoagulant therapy with low
molecular weight heparin (LMWH) or vitamin K antagonists
(VKAs) results in recanalisation in a proportion of patients with
established PVT [8–11]. There are multiple reasons to assume that
successful recanalisation improves clinical outcome. First, an
untreated PVT may extend further into the mesenteric/splenic
venous system, leading to venous infarction. Second, an untreated
PVT may result in accelerated progression of disease as a result of
accelerated ‘parenchymal extinction’ [12]. There is, however, little
clinical evidence as to whether recanalisation following anticoag-
ulant therapy indeed improves clinical outcome.
Currently, no strategies to prevent development of PVT are
available. Nevertheless, a recent randomized trial demonstrated
that a daily prophylactic administration of a prophylactic doseJournal of Hepatology 201of LMWH prevents PVT in patients with compensated cirrhosis,
and in addition appears to delay hepatic decompensation [13].
Although PVT is generally regarded as a deep venous throm-
bosis, it has not yet been established whether the pathophysiol-
ogy of the portal vein thrombus indeed resembles the classical
venous thrombus (i.e., a ﬁbrin-rich thrombus, as opposed to the
platelet-rich thrombus that occurs in systemic arterial thrombo-
sis such as myocardial infarction or stroke). The effect of anti-
platelet drugs on PVT has not yet been explored in the non-liver
transplant setting, which may be due to the bleeding risk associ-
ated with aspirin in patients with esophageal varices [14].
Venous thrombosis
Multiple studies have demonstrated that patients with chronic
liver disease are not protected against venous thrombosis (which
includes deep vein thrombosis (DVT) and pulmonary embolism),
even in the presence of mechanical or pharmacological thrombo-
prophylaxis [15–18]. Some studies indicate that chronic liver dis-
ease is in fact a risk factor for venous thrombosis with a more
than 2-fold increased risk [15], although not all studies agree
[19].
Treatment of venous thrombosis in the general population
during immobilization, hospitalization or following major sur-
gery is typically achieved with LMWH followed by VKAs or by
novel anticoagulant agents, including oral direct factor Xa and
IIa inhibitors [20]. Primary prevention of venous thrombosis in
the general population is achieved by LMWH, the heparin-
derived synthetic pentasaccharide fondaparinux, low-dose
unfractionated heparin, or by oral anti Xa or IIa inhibitors [20].
The oral Xa and IIa inhibitors Rivaroxaban and Dabigatran have
been registered for primary prophylaxis after orthopedic surgery.
There is mounting evidence that thromboprophylactic treatment
is safe in patients with cirrhosis [21] and it would follow that
prophylaxis should not be withheld from patients with liver dis-
ease even in the presence of abnormal routine tests of coagula-
tion. Indications for thromboprophylaxis include hospitalization
and immobilization, surgery, and perhaps also the presence of
(hepatocellular) cancer, as cancer in general is a risk factor for
venous thrombosis.
Arterial thrombosis
The incidence of arterial thrombotic events, including coronary
and cerebrovascular infarctions, was traditionally believed to
occur in a lower frequency in patients with cirrhosis as compared
to the general population [22–24]. Recent studies, however, have
challenged these earlier ﬁndings [25–27]. Patients with non-alco-
holic fatty liver disease (NAFLD) have been repeatedly shown to
have an increased risk for arterial disease, which is in fact the
leading cause of death in this group [28]. As the number of
patients with NAFLD/non-alcoholic steatohepatitis (NASH) is
increasing, the number of patients with both liver and cardiovas-
cular disease will likely increase as well.
For primary prevention of arterial disease in the general pop-
ulation >50 years of age, low dose aspirin therapy may be consid-
ered. Antithrombotic therapy and/or secondary prevention of
cardiovascular events consist of antiplatelet monotherapy (aspi-
rin or clopidogrel) for patients with established coronary artery
disease and dual antiplatelet therapy (aspirin with a P2Y12
receptor blocker) following acute coronary syndromes with3 vol. 59 j 358–366 359
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percutaneous coronary intervention and stent placement [20].
Secondary prevention of ischemic stroke consists of single anti-
platelet therapy or oral anticoagulant therapy. Secondary preven-
tion of arterial events should presumably not be withheld from
patients with cirrhosis, but the risk of bleeding complications
may be increased (see below).
Thrombosis as a contributor to progression of disease
Increasing evidence from animal models of chronic or acute liver
failure suggests that antithrombotic treatment slows down pro-
gression of disease [29–31]. Mechanistic explanations for this
phenomenon include formation of microthrombi resulting in
local ischemia (referred to as ‘parenchymal exctinction’) and
direct activation of disease-promoting cells by coagulation prote-
ases [12]. Also, patients with cirrhosis and inherited thrombo-
philia appear to have a faster disease progression [32], whereas
disease progression in patients with hemophilia in combination
with hepatitis C appears slower [33]. A recent randomized trial
demonstrated that a daily prophylactic administration of a pro-
phylactic dose of LMWH to patients with compensated cirrhosis
may delay hepatic decompensation [13]. The results of this trial
not only indicate that the proposed theory on intrahepatic
thrombus formation as a contributor to progression of disease
is likely correct, but also suggest that intrahepatic thrombosis is
treatable. In addition to this recently published study, a study
examining the effect of warfarin anticoagulation on hepatitis C
recurrence after liver transplantation has been initiated (Clinical-
trials.gov: NCT00180674), and similar studies in the pre-trans-
plant patient are underway, although the choice of
antithrombotic agent is unclear.
Key Points 1
• Anticoagulants have been successfully used to treat
PVT in patients with cirrhosis, and a single study
showed that anticoagulants are effective in prevention
of PVT in patients with cirrhosis
• 
• Patients with cirrhosis are not protected against arterial
thrombosis, and the incidence of arterial events is even
increased in patients with NAFLD/NASH compared
to the general population. Patients with cirrhosis and
an arterial event will often (if not always) receive
antiplatelet therapy which may be associated with a
bleeding risk
• Antithrombotic therapy reduces progression of 
liver diseases in animal models, and a single 
randomized clinical trial showed that LMWH delays
decompensation in patients with compensated cirrhosis
• The best choice of antithrombotic agent as well as safe
dosing regimens for all these indications has not yet
been established
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with cirrhosisAnti-platelet agents
Unlike many anticoagulant drugs, anti-platelet agents do not
require laboratory monitoring for dose adjustments, so many of
the issues regarding monitoring that are present in the use of
anticoagulants in patients with cirrhosis do not apply to anti-
platelet agents. Nevertheless, functional tests are sometimes per-
formed to assess anti-platelet drug efﬁcacy, as some patients
appear to be resistant against aspirin or Clopidogrel [34]. Despite
this, no tests are usually performed to avoid excessive inhibition
of platelet function. Tests to detect anti-platelet-resistance in
patients with cirrhosis may be complicated by thrombocytopenia
and platelet function defects that are already present in the
patient with cirrhosis [35]. As laboratory tests of platelet function
are frequently abnormal in patients with cirrhosis, it may be chal-
lenging to detect efﬁcacy of anti-platelet agents, but the clinical
relevance of laboratory evidence of resistance against anti-plate-
let regimens is unclear.
There is tremendous clinical evidence for the efﬁcacy of aspi-
rin in secondary prevention of arterial disease. The published
study with aspirin in patients with cirrhosis, however, is limited.
Cirrhosis has been listed as an absolute contraindication for aspi-
rin use due to gastrointestinal (GI) bleeding risk [14,36]. Further-
more, patients with ascites may suffer from acute renal failure,
hyponatremia, and diuretic resistance in response to aspirin
treatment [37], although these complications are rare at the
low doses used for antiplatelet therapies. Nevertheless, the num-
ber of patients with cirrhosis that require antiplatelet therapy for
secondary prevention of arterial events (e.g., after coronary stent-
ing) is likely increasing over time due to the increasing preva-
lence of NAFLD/NASH. The currently available evidence
suggests that aspirin is relatively safe in terms of bleeding risk
in patients with cirrhosis, but without signiﬁcant varices, after
coronary artery stenting [38]. On the other hand, use of aspirin
has been associated with an increased risk of a ﬁrst variceal
bleeding in patients with established varices, and therefore, in
these patients aspirin is likely contraindicated for primary, and
perhaps also for secondary prevention [14].
Inhibitors of the P2Y12 receptor, which block ADP-induced
platelet aggregation, have become an integral part of treatment
and prevention of arterial thrombosis. The irreversible P2Y12
blockers Clopidogrel and Ticlopidine were the ﬁrst clinically
approved antiplatelet drugs in this class. Genetic variation and
drug-interaction issues complicate the use of these drugs and
result in variable responses to treatment [39]. The second gener-
ation irreversible P2Y12 inhibitor Prasugrel has the advantage of
a more rapid onset of action and results in a more consistent inhi-
bition of platelet function as compared to Clopidogrel [40]. A
major disadvantage of the irreversible P2Y12 inhibitors is that
they require metabolic activation by the liver, which may result
in unpredictable pharmacokinetics in patients with cirrhosis.
The pharmacokinetics and pharmacodynamics of Clopidogrel
are unaltered in patients with Child A or B cirrhosis [41], yet ‘‘sig-
niﬁcant liver impairment or cholestatic jaundice’’ is stated as
contraindications in the package insert. No pharmacokinetic dif-
ferences in patients with Child B cirrhosis were demonstrated for
Prasugrel [42], and chronic liver disease is not a contraindication
according to the package insert, although caution is advised. The3 vol. 59 j 358–366
JOURNAL OF HEPATOLOGY
reversible P2Y12 inhibitor Ticagrelor does not require metabolic
activation, but is cleared by the liver. Although it has been dem-
onstrated that patients with Child A cirrhosis do not have
impaired pharmacokinetic responses to Ticagrelor [43], severe
chronic liver disease is a contraindication for this drug according
to the package insert. Since most of the P2Y12 blockers state
(severe) liver disease as a contraindication, the role of these drugs
in patients with cirrhosis is unclear. However, since the contrain-
dication appears primarily based on the perceived bleeding risk,
studies on safety of Clopidogrel in these patients appear justiﬁed.
Anecdotal evidence is suggestive of an acceptable safety proﬁle
[38]. The use of P2Y12 inhibitors for prevention of arterial events
in cirrhosis may be limited to those patients without varices,
since the rate of variceal bleeding in patients receiving antiplate-
let agents following stent placement was substantial (12.5%).
Extended-release dipyridamole may be used for speciﬁc arte-
rial indications. It is eliminated primarily by biliary excretion and
undergoes enterohepatic recirculation. Although dipyridamole
has potential beneﬁcial side effects such as reducing progression
of disease (shown in animal models) [44] and improvement of
portal circulation [45], it does worsen renal function in patients
with ascites and increased plasma renin activity [46].
Heparins
Heparins may be considered for prevention or treatment of
venous thrombosis, PVT, and as adjunct treatment in acute arte-
rial thrombosis. Three classes of heparins are currently available;
unfractionated heparin, LMWHs, and the synthetic pentasaccha-
ride Fondaparinux. In the general population, the advantages of
LMWH or pentasaccharide are mode of administration (s.c. vs.
i.v.) and the ﬁxed dose that does not require laboratory monitor-
ing, except in patients with extreme obesity and patients with
renal dysfunction. Unfractionated heparin is routinely monitored
with the aPTT, whereas LMWH dosing can be monitored with
anti-Xa assays in patients without severe liver dysfunction.
The mode of administration of these agents (i.v. for unfrac-
tionated heparin, and s.c. for LMWH and fondaparinux) as well
as the concern for heparin-induced thrombocytopenia (HIT),
however, may limit long-term use. Nevertheless, patients with
cirrhosis have been treated with daily s.c. injections of LMWHs
for up to a year with the aim to either treat or prevent portal vein
thrombosis [8,13]. These prolonged daily s.c. injections are
clearly inconvenient for the patient and may be associated with
poor compliance. Furthermore, skin reactions, which are mainly
type IV delayed hypersensitivity reactions, at the injection site
may occur, which may require a switch to a different LMWH
preparation or alternative anticoagulant therapy [47]. Although
the incidence of delayed-type hypersensitivity reactions towards
LMWH is estimated at 7.5% but may go up to 40% in speciﬁc pop-
ulations (in particular in pregnant women), such problems have
not been reported in the studies performed in patients with cir-
rhosis. Importantly, these adverse events are known to be
under-reported in patients without liver disease, and future stud-
ies in patients with cirrhosis should thus carefully examine the
incidence of skin reactions.
Although the published experience in patients with cirrhosis
is limited, LMWHs appear to have an excellent safety proﬁle in
patients with cirrhosis and venous thrombosis or PVT [8–
10,13,21,48]. Nevertheless, there are important caveats in using
these agents in this patient population. First, LMWH accumula-Journal of Hepatology 201tion is known to occur in patients with renal failure, and thus
patients with cirrhosis and decreased renal function likely
require dose-adjustments. Second, heparins possess anticoagu-
lant activity by virtue of an enhancing effect of the endogenous
anticoagulant antithrombin. Since antithrombin is synthesized
in the liver, plasma levels are frequently decreased in patients
with cirrhosis, which theoretically leads to an unpredictable anti-
coagulant effect. This is especially true in the context of the mul-
tiple other changes in the hemostatic system in patients with
cirrhosis. Indeed, in vitro studies have demonstrated that LMWH
has a more profound anticoagulant effect in plasma from patients
with cirrhosis as compared to plasma from healthy controls [49].
In addition, it has been suggested in patients with cirrhosis that
anti-Xa levels after a standard prophylactic or therapeutic dose
of LMWH fall below the recommended ranges for optimal antico-
agulant control [48]. However, the decreased anti-Xa levels in
these patients appear to be a laboratory anomaly and not a true
indication of anticoagulation effect. In vitro addition of LMWH
to plasma from patients with cirrhosis has demonstrated that
the anti-Xa level subsequently measured in these plasmas is sub-
stantially lower as compared to the levels that were actually
added (recoveries as little as 32% have been reported), whereas
the recovery in normal plasma is around 100% [49,50]. Thus, in
patients with cirrhosis who generally have an acquired anti-
thrombin deﬁciency, the anti-Xa assay underestimates the true
LMWH mass. This laboratory anomaly will cause a falsely low
level of anti-Xa activity and may lead to incorrect and possibly
dangerous dose escalations. On the other hand, the anticoagulant
potency of LMWH appears increased in patients with cirrhosis,
which points to a requirement for dose-reductions. Clinicians
need to be aware of these caveats, and clinical studies on the
risk/beneﬁt of different dosing strategies of these agents are
required in order to formulate liver-speciﬁc guidelines. A more
reliable monitoring test would assist in these studies. The throm-
bin generation test might hold promise as such a test, but a major
problem is that the test is relatively complex and not available in
the routine clinical laboratory. Alternatively, point of care tests
such as thromboelastography may be useful for LMWH monitor-
ing, but studies assessing usefulness of this technique and to
establish target ranges have not been published in the cirrhosis
population.
Whether similar monitoring problems also occur with unfrac-
tionated heparin or fondaparinux has not yet been assessed. An
additional problem with monitoring of unfractionated heparin
is that the aPTT, which is instrumental in dosing this agent, is
already prolonged in many patients with cirrhosis, and therefore
aPTT target ranges for these patients are unclear.
Vitamin K antagonists
VKAs are still the cornerstone of long-term anticoagulant treat-
ment in the general medical population. The major issue with
VKA use is the absolute requirement for regular monitoring of
the anticoagulant intensity by the International Normalized Ratio
(INR). INR target ranges for different indications have been estab-
lished, and dose adjustments are made when a patient is out of
range. It has been well established that an INR below the target
range increases this risk of (re)thrombosis, whereas an INR above
the target range increases bleeding risk.
VKAs result in decreased functional levels of the vitamin
K-dependent procoagulant proteins factor VII, IX, X, and II. In3 vol. 59 j 358–366 361
Review
addition, VKAs reduce functional levels of the anticoagulant pro-
teins C and S, but the net result of VKAs is a reduction of hemo-
static potential.
The major concern with the use of VKAs in patients with cir-
rhosis is that the target INR for patients with cirrhosis and an
already prolonged INR is unclear. It is now well established that
while a prolonged INR due to VKAs indicates a decreased hemo-
static potential, a prolonged INR due to cirrhosis is unrelated to
hemostatic capacity [1,51]. Furthermore, it is difﬁcult to interpret
an INR that is elevated due to a combination of cirrhosis and
VKAs since the impact of VKAs on coagulation is so different from
the impact of the coagulation abnormalities of cirrhosis on the
clotting system. Finally, it has been demonstrated by multiple
independent groups that the between-laboratory variability of
the INR in patients with cirrhosis is unacceptably high [52–54],
which complicates VKA monitoring by the INR in patients with
cirrhosis even further.
The use of VKAs in patients with cirrhosis is thus likely asso-
ciated with an unfavorable risk/beneﬁt ratio, in particular in
patients with high INRs prior to VKA initiation, as an optimal
anticoagulant intensity will be difﬁcult to achieve. Indeed, the
use of VKAs in patients with cirrhosis has been associated with
an increased risk of bleeding complications [18,55]. There is a
need for a more reliable monitoring test for intensity of VKA anti-
coagulation in the patient with cirrhosis. Thrombin generation
tests or thromboelastography may have a better performance
as compared to the INR, but studies examining this are still lack-
ing. Another possible alternative towards monitoring of VKAs in
patients with cirrhosis is measurements of activity levels of one
of the vitamin K-dependent factors (for example FII), but the tar-
get FII level for optimal anticoagulant activity has not yet been
established.
New-generation oral anticoagulants
Two novel oral anticoagulants have recently been approved for
clinical use. Rivaroxaban is a direct factor Xa inhibitor, and Dabig-
atran is a direct factor IIa inhibitor [56]. Unlike VKAs, both agents
inhibit a single coagulation protease, and unlike heparins, both
agents are independent of antithrombin. Both agents do not
require laboratory monitoring in the general population.
Although this is considered as a major advantage of these drugs,
it is at the same time also a disadvantage as it increases the risk
for non-compliance, which is rapidly detected in patients using
VKAs as a drop in the INR. Further advantages of these drugs
are the mode of administration (oral) and lack of heparin-induced
thrombocytopenia. These new drugs would potentially be
applicable in both long- and short-term anticoagulant strategies
including prevention or treatment of venous thrombosis,
prevention or treatment of PVT and prevention of disease
progression.
Potential advantages of these drugs over VKAs are the wider
therapeutic window. Nevertheless, monitoring of the new drugs
may be required in patients with liver disease. Laboratory meth-
odologies for monitoring these new drugs are still in develop-
ment, and validation in patients with cirrhosis will be required.
A major advantage of the new drugs over heparins is the mode
of administration. In particular the long-term anticoagulant reg-
imens that are currently applied to patients with PVT may be
improved substantially by switching to oral agents.362 Journal of Hepatology 201Rivaroxaban
There are little published clinical studies with Rivaroxaban in
patients with cirrhosis, as they were excluded from clinical trials.
Nevertheless, there is a warning to avoid Rivaroxaban in patients
with Child B and C cirrhosis according to the package insert,
which is related to a (perceived) bleeding risk. Furthermore, sig-
niﬁcant increases in Rivaroxaban exposure are observed in
patients with Child B cirrhosis [57]. In addition, Rivaroxaban
was associated with a higher risk for GI bleeding compared to
warfarin in patients with adequate liver function [58]. Finally,
Rivaroxaban is cleared primarily by the kidneys (66%) and liver
(34%) [59]. Patients with cirrhosis with or without concomitant
renal failure, and in particular patients with the hepatorenal syn-
drome may thus not be ideal candidates for Rivaroxaban, and
dose adjustments may be required.
A major concern regarding the use of Rivaroxaban is the lack
of established reversal agents. Given its half life of 5–13 hours,
drug discontinuation is insufﬁcient when an acute bleeding
occurs. One study in healthy volunteers has demonstrated that
a prothrombin complex concentrate reverses the anticoagulant
effect of Rivaroxaban [60]. A second study, in which reversal
agents were added in vitro to plasma from healthy volunteers
receiving Rivaroxaban, showed (partial) reversal of the anticoag-
ulant effect by both (activated) prothrombin concentrates and
recombinant factor VIIa [61].
Dabigatran
There is also little clinical experience with Dabigatran in patients
with cirrhosis, but contrary to Rivaroxaban, Dabigatran is not
explicitly contraindicated for patients with cirrhosis. The phar-
macokinetics of Dabigatran is not different between patients with
Child B cirrhosis and healthy individuals [62]. Dabigatran is
mainly (80%) eliminated via the kidneys, and in severe renal fail-
ure bioaccumulation occurs [63]. Patients with cirrhosis and
renal failure may thus not be ideal candidates for Dabigatran,
and dose adjustments may be required.
Similar to Rivaroxaban, the long half life of Dabigatran (12–
14 hours) renders drug discontinuation alone insufﬁcient in case
of acute bleeding. Dabigatran may be neutralized soon after
ingestion by gastric lavage or charcoal administration, and in
severe cases acute hemodialysis may be considered [64]. A study
in which reversal agents were added in vitro to plasma from
healthy volunteers receiving Dabigatran showed (partial) rever-
sal of the anticoagulant effect by both (activated) prothrombin
concentrates and recombinant factor VIIa [61].
In patients without liver dysfunction, Dabigatran has been
associated with an increased risk of lower gastrointestinal bleed-
ing, which may be related to the poor bioavailability of the drug,
which results in high concentration of the drug in feces [65]. Fur-
thermore, over 10% of patients in phase III trials of Dabigatran
complained of dyspepsia [66], which has been attributed both
to high levels of the drug in the colon and to the high concentra-
tion of tartaric acid in the capsule. This side effect is especially
worrisome since the co-administration of Pantoprazole decreases
the effective therapeutic area under the curve for Dabigatran by
22% [67]. Whether these pharmacokinetic interactions are class
effects and whether they are clinically pertinent have not been
completely determined. These considerations may limit the
applicability of Dabigatran in patients with moderate or severe
cirrhosis.3 vol. 59 j 358–366
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• Patients with cirrhosis frequently have profound
alterations in their hemostatic system. The net effect
of these changes is a ‘rebalanced’ hemostatic system.
This new hemostatic balance, however, is precarious,
placing patients at risk for both bleeding and thrombotic
complications
• Although patients with cirrhosis may have multiple
indications for antithrombotic therapy to prevent or treat
thrombosis, there is little published experience with
antithrombotic therapy in this patient population
• A number of possible antiplatelet or anticoagulant
drugs are available for clinical use, and all these drugs
have advantages and disadvantages in patients with
cirrhosis. Most published clinical trials on efficacy and
safety of antithrombotic drugs have excluded patients
with cirrhosis
• Clinical trials in patients with cirrhosis are thus 
urgently required. Such trials should examine, for each
indication, the drug with the best risk/benefit ratio in
terms of efficacy, safety, and monitoring. In addition,
these clinical trials should carefully explore dosing
regimens, in particular in patients with advanced
disease or complications, such as renal failure
A practical approach to prevention or treatment of
thrombosis in patients with liver disease
As outlined in the previous sections, we believe that there are
multiple indications for antithrombotic treatment in patients
with liver disease. Both prevention and treatment of thromboses
may require antithrombotic therapy, but due to the lack of clini-
cal data, the type of drug and dosing are in most instances
unclear. A more rational approach to antithrombotic therapy
requires extensive clinical and laboratory research, and fortu-
nately many groups are currently embarking on such journeys.
However, the practicing clinician is at present facing dilemmas
on if and how to apply antithrombotic therapy in patients with
liver disease. Here we will provide some guidance on how to
approach prevention or treatment of the various types of throm-
bosis at present, but we need to stress that none of these
approaches is evidenced-based.
Portal vein thrombosis
We believe that anticoagulant therapy with the aim of preventing
PVT at present should only be considered in the context of clinical
trials. Insufﬁcient data on efﬁcacy and safety of anticoagulation to
avoid PVT is currently available to justify widespread use of this
approach.
Although it is uncertain whether treatment of PVT in patients
with cirrhosis improves outcome, more and more clinicians will
be inclined to start anticoagulant treatment. We believe LMWH
is at present the anticoagulant of choice, as the available clinical
data suggest LMWH to be effective and safe in patients with liver
disease. We suggest conservative dosing, in particular in patients
with advanced disease, and in those patients with risk factors forJournal of Hepatology 201bleeding, such as renal failure and severe thrombocytopenia.
Laboratory monitoring by anti-Xa assays is not recommended
since these values likely underestimate the in vivo anticoagulant
status. Given the high rates of bleeding and the lack of a suitable
target INR, vitamin K antagonists are discouraged in the treatment
of PVT.
Venous thrombosis
We believe that thromboprophylaxis to prevent venous throm-
bosis should not be withheld from patients with cirrhosis, even
in the presence of profoundly prolonged INRs. Speciﬁcally, we
recommend LMWH thromboprophylaxis in all situations (hospi-
talization, immobilization, and post-surgery) in which patients
without liver disease would receive thromboprophylaxis. Dosing
regimens may be adapted in patients with risk factors for bleed-
ing such as renal failure or profound thrombocytopenia. In those
patients with clear contraindications for anticoagulant treat-
ment, mechanical thromboprophylaxis (for example using com-
pression stockings or pneumatic compression devices) should be
considered. Monitoring of LMWH prophylaxis should not be
performed. If anti-Xa levels are absolutely required, for example
in patients with severe renal failure, we recommend assessing
anti-Xa levels only with a test kit in which the test plasma is
supplemented with antithrombin to avoid falsely-low anti-Xa
levels as a consequence of the patients’ low plasma antithrom-
bin levels.
Treatment of venous thrombosis should be initiated with
LMWHs, and may be continued with VKAs or prolonged LMWH
administration. Studies on optimal dosing regimens for VKAs
are urgently required, and until these studies become available,
we recommend conservative dosing. When prolonged LMWH
administration instead of a switch to VKAs is chosen, this
should be performed with great care. Reductions in LMWH or
VKA dosages may be required in those patients with risk
factors for bleeding, such as renal failure or severe
thrombocytopenia.
Arterial thrombosis
Aspirin prophylaxis for primary or secondary prevention of arte-
rial events and P2Y12 inhibitors for secondary prevention
should not be withheld from all patients with cirrhosis, but
there may be (low-risk) patients in whom the risk/beneﬁt
proﬁle is unfavorable. Although data are largely lacking, the
bleeding risk of primary and secondary prophylaxis is likely
increased in patients with liver disease compared to the general
population, in particular in those patients with varices. Never-
theless, the beneﬁt of prophylaxis, particularly in high-risk
patients, such as patients with NASH-related cirrhosis, likely
justiﬁes the bleeding risk.Antithrombotic therapy to delay disease progression
Based on one study, anticoagulation using LMWH appears to
delay progression of liver disease. Although these results suggest
that antithrombotic therapy may be a fundamentally novel
approach to treat patients with cirrhosis, such strategies should
at present only be performed in the context of well-designed
clinical trials.3 vol. 59 j 358–366 363
Table 1. Antithrombotic drugs that are registered for clinical use and recommended for prevention or treatment of venous or arterial events in the most current
guidelines. Their mechanism of action, potential indications in patients with liver disease, and advantages or disadvantages are shown.
Drug Mechanism (Potential) indications Pros Cons
Aspirin Cyclooxygenase inhibitor Treatment/prevention arterial 
thrombosis
Cost, experience and proven 
limited data suggests safety in 
cirrhosis
detect, GI bleeding risk
Clopidogrel Reversible P2Y12 
inhibitor
Secondary prevention arterial 
thrombosis
No change in 
pharmacokinetics in Child-
Pugh A and B cirrhosis
Variable response to 
treatment due to genetics and 
drug-interaction, bleeding risk
Prasugrel Reversible P2Y12 
inhibitor
Secondary prevention arterial 
thrombosis
More consistent inhibition of 
platelet function compared to 
clopidogrel
Bleeding risk
Tricagrelor Irreversible P2Y12 
inhibitor
Secondary prevention arterial 
thrombosis
Does not require metabolic 
activation by the liver
Bleeding risk
Extended 
release-
dipyridamole
Adenosine uptake 
inhibitor and 
phosphodiesterase 
inhibitor
Treatment/prevention 
ischemic stroke circulation
Affects renal function in 
patients with ascites
Unfractionated 
heparin
Antithrombin-dependent 
inhibition of FXa and 
thrombin
Prevention DVT, prevention/
treatment acute coronary 
syndromes, cardiac surgery
Cost, fully reversible with 
protamine
Risk of HIT, dependent on 
antithrombin monitoring with 
long-term treatment, mode of 
administration (i.v.)
Low molecular 
weight heparin
Antithrombin-dependent 
inhibition of FXa and (to 
a lesser extent) thrombin
Prevention/treatment DVT 
and PVT
Reduced risk for HIT, route 
of administration (s.c. vs. i.v. 
for UFH)
Antithrombin dependence, 
issues with anti Xa monitoring, 
only partial reversal by 
protamine, not ideal for long-
term treatment, accumulation 
in renal failure
Fondaparinux Antithrombin-dependent 
inhibition of FXa
Prevention/treatment DVT 
and PVT
Further reduction in risk 
of HIT compared to other 
heparins, synthetic drug 
Antithrombin dependence, 
issues with anti Xa monitoring, 
no established reversal 
agent, not ideal for long-term 
treatment, accumulation in 
renal failure
Vitamin K 
antagonists
Reduce functional levels 
of vitamin K-dependent 
proteins
Prevention/treatment DVT 
and PVT
Cost, experience and proven 
mode of administration 
Issues with monitoring in 
patients with already elevated 
INR, bleeding
Rivaroxaban Direct factor Xa inhibitor Prevention/treatment DVT 
and PVT
Lack of antithrombin 
dependence, mode of 
administration, wider 
therapeutic window than 
VKAs
Lack of experience, no 
established antidote, GI 
bleeding risk, accumulation in 
renal and liver disease 
Dabigatran Direct thrombin inhibitor Prevention/treatment DVT 
and PVT
Lack of antithrombin 
dependence, mode of 
administration, wider 
therapeutic window than 
vitamin K antagonists
Lack of experience, no 
established antidote, GI 
bleeding risk, dyspepsia, 
interaction with pantoprazole, 
accumulation in renal failure
Aspirin resistance difficult to
efficacy in general population,
Beneficial effects on portal
aPTT difficult, not ideal for
efficacy in general population,
ReviewConclusions
Anticoagulant therapy in the patientwith cirrhosis is amajor chal-
lenge. As the hemostatic system in cirrhosis is frequently altered
substantially, compared tohealthy individuals, it is likely that anti-
coagulant drug regimens applied in the general population will
result in unpredictable effects in the patient with cirrhosis. More-
over, monitoring of anticoagulant therapy is difﬁcult as the avail-
able monitoring strategies are developed for use in individuals
with a competent hemostatic system prior to initiation of antico-
agulant therapy. For these reasons, it will be difﬁcult to achieve
an optimal intensity of the anticoagulant treatment which will
increase the risks of thrombosis, recurrent thrombosis, or bleeding.364 Journal of Hepatology 201For many of the available agents, little or no published expe-
rience in the patient with cirrhosis exists. Nevertheless, we
believe it is relevant that the hepatology community is aware
of the (theoretical) advantages and disadvantages of the available
drugs, which we have described in this review and are summa-
rized in Table 1. The awareness that patients with cirrhosis
may be candidates for prophylactic or therapeutic anticoagulant
intervention is increasing. Similarly, the proportion of patients
requiring anticoagulant therapy is likely increasing (for example
due to the increasing incidence of NASH). Clinical and laboratory
studies on mechanisms, efﬁcacy, and safety of the various anti-
thrombotic strategies will be required in patients with cirrhosis.
Such studies will assist in future management decisions as well in3 vol. 59 j 358–366
JOURNAL OF HEPATOLOGY
design of clinical trials assessing efﬁcacy and safety of various
antithrombotic regimens. For some of the newer drugs, including
Rivaroxaban and Dabigatran, the theoretical disadvantages such
as drug accumulation with a resulting bleeding risk may prohibit
clinical trials in patients with advanced disease. Nevertheless, a
potentially important new indication for antithrombotic therapy
in patients with mild to moderate cirrhosis is prevention of pro-
gression of disease, and in such patients the new oral anticoagu-
lants may be applicable. In these patients with compensated
disease, the advantages of the new drugs may outweigh the
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